Are semaglutide tablets as effective as injections for weight loss?

What the OASIS 4 trial tells us about the tablet's effectiveness

When the MHRA approved the Wegovy tablet in June 2026, the supporting data came primarily from OASIS 4: a 64-week, placebo-controlled, phase-3 trial involving 307 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. Participants taking the 25mg oral dose lost an average of 13.6% of their body weight, compared with 2.4% in the placebo group. Among those who adhered fully to the regimen, the figure reached around 17%. That framing matters, the 17% result reflects consistent, uninterrupted use, not the average across everyone who started. If you're wondering whether the semaglutide tablet is as effective as the injection, these trial numbers are a good place to start before drawing any conclusions. A fuller look at how the tablet compares with the injection is worth reading alongside these numbers. The most common side effects in the trial were gastrointestinal: nausea, vomiting and diarrhoea affected around 74% of tablet users versus 42% on placebo, though most were mild-to-moderate and tended to settle as the body adjusted. The NHS semaglutide patient information covers what to expect in more detail.

How the injection's results stack up (and where the 7.2mg dose changes the picture

The 2.4mg weekly injection (Wegovy) produced roughly 15% average weight loss in the STEP 1 trial over 68 weeks) a longer study with a larger population than OASIS 4, which makes a clean head-to-head comparison difficult. The injection had a head start: it has been available in the UK longer, has more post-approval data, and the standard 2.4mg maintenance dose is well characterised. Then, in January 2026, the MHRA approved a higher 7.2mg maintenance dose for the injection, with trial data reporting around 20.7% average weight loss over 72 weeks at that level. A dedicated single-dose 7.2mg pen followed in April 2026. That shifts the landscape: the injection now spans a wider results range than the tablet, at least based on current evidence. What the tablet offers in return is practical: no needles, no refrigeration, and a routine that fits neatly before the kettle goes on each morning. For people who find injections a barrier, that trade-off can be clinically meaningful in its own right. Comparing the tablet and injection side by side lays out the practical differences alongside the numbers.

Why the right format depends on more than the weight-loss percentage

Clinical trials measure averages across a study population. Individual results vary based on starting weight, metabolic profile, how consistently the medicine is taken, dietary changes, and activity levels. A person who takes the tablet reliably, every morning before eating, may well achieve results that exceed the trial average, just as someone who misses injections or struggles with nausea at higher doses may see less. The absorption mechanism for the tablet also matters: oral semaglutide uses an enhancer called SNAC to cross the gut wall, and because food and drink dramatically reduce absorption, taking it correctly is non-negotiable. That 30-minute empty-stomach window is not a suggestion. On the cost side, what the Wegovy tablet costs privately in the UK is a practical question worth addressing early in your decision. Neither format is universally superior. The right choice is the one a prescriber concludes suits your health history, your lifestyle, and your clinical needs, which is why format preference is part of the conversation at consultation, not a decision made in isolation. Weighing up whether tablets or injections fit your situation can help you arrive at that consultation with clearer questions.

What the licensing and guidelines actually say

Both forms carry a Black Triangle (▼) designation, meaning the MHRA is collecting additional safety data on an ongoing basis, standard for newly approved or recently extended medicines. The tablet is licensed for adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related condition, taken with a reduced-calorie diet and increased physical activity. That mirrors the injection's licensed population broadly, though the injection's MHRA-approved 7.2mg dose currently carries a BMI-30-and-above-only restriction. NICE has appraised the 2.4mg injection under technology appraisal TA875 but has not yet evaluated the tablet, a NICE appraisal process would need to run first before NHS coverage becomes possible. For now, the tablet is private prescription only. Both products are prescription-only medicines; a registered prescriber must assess suitability before either can be dispensed. No comparison of formats substitutes for that assessment. If you'd like to discuss which option may suit you, start your free consultation with our prescribers at nume.